Fractyl Health
GUTSFractyl Health is a clinical-stage metabolic therapeutics company dedicated to developing novel treatments for obesity and type 2 diabetes.
$126.92M+70.5%
Table of contents
Earnings
Next report
Aug 11, 2026 (In 3 weeks)EPS estimate-$0.15
Competitors
By market cap
By revenue growth
Profile
Fractyl Health is a clinical-stage metabolic therapeutics company dedicated to developing novel treatments for obesity and type 2 diabetes. The company focuses on addressing the root causes of metabolic disease through procedural and gene therapy interventions designed to provide durable weight maintenance and disease remission without the need for chronic daily or weekly pharmacotherapy.
Competitive position
Fractyl Health is a pioneer in duodenal mucosal resurfacing and pancreatic gene therapy, targeting patients who discontinue GLP-1RA therapies.
GeographiesUnited States
Customer segmentsHealthcare providers, Obesity and T2D patients
Business modelR&D-stage biotechnology, Medical device manufacturing
SuppliersAAV vector manufacturers, Medical-grade component suppliers, Clinical research organizations (CROs)
CustomersMetabolic disease specialists, Bariatric surgeons, Gastroenterology departments
CountryUnited States of America
Listed2024
Employees94.0
CEOHarith Rajagopalan
SectorHealthcare
IndustryBiotechnology
Websitefractyl.com
FilingsSEC EDGAR
Questions, answered.
- What is Fractyl Health's market cap?
- Fractyl Health (GUTS) has a market capitalization of $126.9M and trades on NASDAQ.
- Who are Fractyl Health's competitors?
- Fractyl Health's key competitors include Viking Therapeutics, Eli Lilly, EyePoint, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Fractyl Health partner with?
- Fractyl Health's notable partners include Eli Lilly, Novo Nordisk.
- Where is Fractyl Health headquartered?
- Fractyl Health is headquartered in United States of America and employs approximately 94 people. It has been publicly traded since 2024.